Ocular Therapeutix Stock Earnings Per Share
| OCUL Stock | USD 7.51 0.07 0.94% |
Ocular Therapeutix fundamentals help investors to digest information that contributes to Ocular Therapeutix's financial success or failures. It also enables traders to predict the movement of Ocular Stock. The fundamental analysis module provides a way to measure Ocular Therapeutix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocular Therapeutix stock.
Ocular | Earnings Per Share |
Ocular Therapeutix Company Earnings Per Share Analysis
Ocular Therapeutix's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Ocular Therapeutix Earnings Per Share | (1.22) X |
Most of Ocular Therapeutix's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ocular Therapeutix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ocular Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Ocular Therapeutix is extremely important. It helps to project a fair market value of Ocular Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Ocular Therapeutix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ocular Therapeutix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ocular Therapeutix's interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Ocular Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Ocular Therapeutix has an Earnings Per Share of -1.22 times. This is 114.58% lower than that of the Pharmaceuticals sector and 74.53% lower than that of the Health Care industry. The earnings per share for all United States stocks is 139.1% higher than that of the company.
Ocular Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ocular Therapeutix's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ocular Therapeutix could also be used in its relative valuation, which is a method of valuing Ocular Therapeutix by comparing valuation metrics of similar companies.Ocular Therapeutix is currently under evaluation in earnings per share category among its peers.
Ocular Therapeutix Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ocular Therapeutix from analyzing Ocular Therapeutix's financial statements. These drivers represent accounts that assess Ocular Therapeutix's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ocular Therapeutix's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.3B | 532.5M | 216.0M | 356.0M | 1.4B | 1.4B | |
| Enterprise Value | 1.1B | 427.3M | 178.0M | 243.6M | 1.0B | 1.1B |
Ocular Therapeutix ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ocular Therapeutix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ocular Therapeutix's managers, analysts, and investors.Environmental | Governance | Social |
Ocular Fundamentals
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (2.96) % | ||||
| Current Valuation | 877.94 M | ||||
| Shares Outstanding | 159.02 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 85.06 % | ||||
| Number Of Shares Shorted | 11.6 M | ||||
| Price To Earning | (2.69) X | ||||
| Price To Book | 3.79 X | ||||
| Price To Sales | 18.74 X | ||||
| Revenue | 63.72 M | ||||
| Gross Profit | (69.54 M) | ||||
| EBITDA | (176.14 M) | ||||
| Net Income | (193.51 M) | ||||
| Cash And Equivalents | 134.54 M | ||||
| Cash Per Share | 1.75 X | ||||
| Total Debt | 75.78 M | ||||
| Debt To Equity | 0.90 % | ||||
| Current Ratio | 6.14 X | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (134.68 M) | ||||
| Short Ratio | 12.39 X | ||||
| Earnings Per Share | (1.22) X | ||||
| Target Price | 17.45 | ||||
| Number Of Employees | 274 | ||||
| Beta | 1.33 | ||||
| Market Capitalization | 1.19 B | ||||
| Total Asset | 457.94 M | ||||
| Retained Earnings | (891.08 M) | ||||
| Working Capital | 399.63 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 5.38 M | ||||
| Net Asset | 457.94 M |
About Ocular Therapeutix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ocular Therapeutix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocular Therapeutix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocular Therapeutix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Ocular Therapeutix Piotroski F Score and Ocular Therapeutix Altman Z Score analysis. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share | Quarterly Revenue Growth 0.154 | Return On Assets | Return On Equity |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.